It was found that metformin inhibits SW-480 cell growth in a time-dependent manner, and its possible mechanisms of antitumor effects include the following: 1. Improvement of hyperglycemic and hyperinsulinemic states; 2. Inhibition of cellular mitochondrial electron transfer, inhibition of oxidative phosphorylation, and can lead to apoptosis by affecting respiratory chain complex 1 in hepatocytes, activation of AMP-activated protein kinase, and inhibition of mammalian target proteins of rapamycin. 3. Corrects AGEs-induced cell cycle disorder by inhibiting CyclinD1 expression and effectively inhibits AGEs-induced telomerase activity, thus exerting an inhibitory effect on AGEs-induced SW-480 cell proliferation and attenuating the malignancy of SW-480 cells. Professor Michael Pollak of McGill University in Montreal, Canada, summarized the research evidence to date on metformin and the risk of cancer development. The results show that metformin, in addition to improving glycemic control in patients with type 2 diabetes, potentially reduces the risk of developing certain cancers and has the potential to improve the prognosis of certain patients with combined cancer type 2 diabetes.